Novavax/$NVAX
1D1W1MYTD1Y5YMAX
Capital at risk
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
- Ticker
- $NVAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 749
- Headquarters
- Gaithersburg, United States
- Website
- www.novavax.com
Novavax Metrics
BasicAdvanced
$1.5B
-
-$1.52
2.42
-
Price and volume
Market cap
$1.5B
Beta
2.42
52-week high
$11.97
52-week low
$6.20
Average daily volume
4.8M
Financial strength
Current ratio
2.333
Quick ratio
2.233
Long term debt to equity
-153.748
Total debt to equity
-155.904
Interest coverage (TTM)
-5.20%
Profitability
EBITDA (TTM)
-101.552
Gross margin (TTM)
-2.56%
Net profit margin (TTM)
-59.87%
Operating margin (TTM)
-28.85%
Effective tax rate (TTM)
-0.98%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
-6.51%
Return on equity (TTM)
323.66%
Valuation
Price to revenue (TTM)
3.668
Price to book
-8.04
Price to tangible book (TTM)
-5.05
Price to free cash flow (TTM)
-35.274
Free cash flow yield (TTM)
-2.83%
Free cash flow per share (TTM)
-0.264
Growth
Revenue change (TTM)
-61.64%
Earnings per share change (TTM)
-159.61%
3-year revenue growth (CAGR)
-36.25%
10-year revenue growth (CAGR)
36.01%
3-year earnings per share growth (CAGR)
-40.03%
10-year earnings per share growth (CAGR)
-22.68%
What the Analysts think about Novavax
Analyst ratings (Buy, Hold, Sell) for Novavax stock.
Analyst projections of the future price of Novavax stock.
Bulls say / Bears say
Novavax raised its 2026 adjusted revenue forecast to $235–$275 million after beating Q2 expectations, driven by licensing-driven milestone payments that offset waning vaccine demand (Reuters)
Sanofi partnership has progressed to advanced Phase 3 regulatory discussions for the COVID-19-Influenza combination vaccine, with mid-2027 completion of manufacturing technology transfer set to trigger a $75 million milestone payment (Novavax IR)
Novavax advanced its C. difficile vaccine candidate into pre-IND FDA interactions and initiated GMP manufacturing, positioning the program for clinical entry as early as 2027 and diversifying its pipeline (Novavax IR)
Total Q2 2026 revenue plunged 76% year-over-year to $57 million, with licensing, royalties, and other revenue down 83%, underscoring weak commercial momentum and heavy reliance on partner milestones (Novavax IR)
The company reported a $53 million net loss in Q2 2026 and a $62.9 million loss for the first half of 2026, a stark reversal from prior-year profitability, highlighting ongoing operational deficits (Novavax IR)
The $75 million Sanofi manufacturing technology transfer milestone is not expected until mid-2027, delaying a key cash inflow and creating near-term funding uncertainty (Novavax IR)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Novavax Financial Performance
Revenues and expenses
Novavax Earnings Performance
Company profitability
Upcoming events
No upcoming events
Novavax News
AllArticlesVideos
Funds containing Novavax
AllUSDEURGBP
Fund name | Fund size | $NVAX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.13% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.13% |
iShares Healthcare Innovation£DRDR | £1B | 0.13% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.09% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.